Literature DB >> 7934617

Increased activities of cathepsin B and other lysosomal hydrolases in fibroblasts and bone tissue cultured in the presence of cysteine proteinases inhibitors.

J P Montenez1, J M Delaissé, P M Tulkens, B K Kishore.   

Abstract

Leupeptin is an established, reversible inhibitor of cathepsin B, a lysosomal cysteine proteinase. Yet, in rat fibroblasts as well as in foetal mouse calvaria, we observed an increase of the activity of cathepsin B in homogenates of cells and tissue harvested after culture in the presence of leupeptin. This effect was also seen for other lysosomal hydrolases, namely sphingomyelinase, N-acetyl-beta-glucosaminidase, arylsulphatase A and phospholipase A1 in fibroblasts, and beta-glucuronidase in mouse calvaria. In calvaria, antipain, another reversible cysteine proteinase inhibitor, caused a similar effect, whereas E-64, an irreversible inhibitor, was consistently inhibitory of the cathepsin B activity; yet it also caused an increase of beta-glucuronidase activity. The effect of leupeptin in fibroblasts was dose and time-dependent, required the continuous presence of the inhibitor, and was not dependent from protein synthesis. Actually, addition of cycloheximide caused a severe loss of activity of cathepsin B and of sphingomyelinase. In the presence of both cycloheximide and leupeptin, however, these two activities were retained to a value corresponding to that found in excess in cells cultivated with leupeptin alone. The data therefore suggests that leupeptin exerts the effects described in this paper by preventing the degradation of cathepsin B, sphingomyelinase and probably several other lysosomal hydrolases by cysteine proteinases. We therefore propose that cysteine proteinases play a key role in the control of the steady-state levels of these enzymes in normal conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7934617     DOI: 10.1016/0024-3205(94)00659-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Intracochlear perfusion of leupeptin and z-VAD-FMK: influence of antiapoptotic agents on gunshot-induced hearing loss.

Authors:  Loubna Abaamrane; Florent Raffin; Sébastien Schmerber; Isabelle Sendowski
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-19       Impact factor: 2.503

2.  Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.

Authors:  Catera L Wilder; Charlene Walton; Valencia Watson; Fermin A A Stewart; Jade Johnson; Shelly R Peyton; Christine K Payne; Valerie Odero-Marah; Manu O Platt
Journal:  Int J Biochem Cell Biol       Date:  2016-08-31       Impact factor: 5.085

3.  Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors.

Authors:  Andrea M Zuhl; Charles E Nolan; Michael A Brodney; Sherry Niessen; Kevin Atchison; Christopher Houle; David A Karanian; Claude Ambroise; Jeffrey W Brulet; Elizabeth M Beck; Shawn D Doran; Brian T O'Neill; Christopher W Am Ende; Cheng Chang; Kieran F Geoghegan; Graham M West; Joshua C Judkins; Xinjun Hou; David R Riddell; Douglas S Johnson
Journal:  Nat Commun       Date:  2016-10-11       Impact factor: 14.919

Review 4.  Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.

Authors:  Luana Xavier Soares Gomes Moura Fé; Eliane Pereira Cipolatti; Martina Costa Cerqueira Pinto; Suema Branco; Fábio César Sousa Nogueira; Gisela Maria Dellamora Ortiz; Anderson de Sá Pinheiro; Evelin Andrade Manoel
Journal:  Med Res Rev       Date:  2022-06-28       Impact factor: 12.388

5.  Dynamic Model of Protease State and Inhibitor Trafficking to Predict Protease Activity in Breast Cancer Cells.

Authors:  W Andrew Shockey; Christopher A Kieslich; Catera L Wilder; Valencia Watson; Manu O Platt
Journal:  Cell Mol Bioeng       Date:  2019-06-19       Impact factor: 2.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.